Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.51 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125860 | 1.00 | REV1 (0.54) | REV1ABCB1ABCC1KDM4EABCG2 | |
| SCHEMBL5128254 | 0.96 | FAAH (0.48) | REV1ABCB1ABCC1KDM4EABCG2 | |
| SCHEMBL5131977 | 0.94 | REV1 (0.57) | REV1ABCB1ABCC1KDM4EABCG2 | |
| SCHEMBL5125747 | 0.89 | REV1 (0.64) | REV1ABCB1ABCC1KDM4EABCG2 | |
| SCHEMBL5131159 | 0.85 | REV1 (0.56) | REV1ABCB1ABCC1KDM4EABCG2 | |
| SCHEMBL5128393 | 0.85 | REV1 (0.69) | REV1ABCB1ABCC1KDM4EABCG2 | |
| SCHEMBL5125365 | 0.85 | ABCB1 (0.69) | REV1ABCB1ABCC1KDM4EABCG2 | |
| SCHEMBL5131895 | 0.84 | SIGMAR1 (0.58) | ABCB1ABCC1KDM4EABCG2MAPT | |
| SCHEMBL5130886 | 0.84 | REV1 (0.67) | REV1ABCB1ABCC1KDM4EABCG2 | |
| SCHEMBL5128244 | 0.83 | FAAH (0.51) | REV1ABCB1ABCC1KDM4EABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005077903-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED TETRAHYDROISOQUINOLINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | MCHR1, MCHR2, MC1R | REV1 2490/4885ABCB1 2755/4885ABCC1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.